May 23, 2013 7:17 AM ET

Biotechnology

Company Overview of Callisto Pharmaceuticals, Inc.

Company Overview

Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The company’s lead drug candidates comprise Plecanatide, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant irritable bowel syndrome; and SP-333, a second generation GC-C receptor agonist, which is in pre-clinical development to treat gastrointestinal inflammatory diseases. It develops plecanatide, which under Phase II/III clinical trials and is intended for the treatment of chronic idiopathic constipation. The company was founded in 1996 and is he...

Detailed Description

420 Lexington Avenue

Suite 1609

New York, NY 10170

United States

Founded in 1996

11 Employees

Phone:

212-297-0010

Fax:

212-297-0020

www.callistopharma.com

Key Executives for Callisto Pharmaceuticals, Inc.

Chief Executive Officer
Age: 65
Principal Financial Officer
Age: 64
Chief Scientific Officer of Synergy Pharmaceuticals Inc
Age: 54
Associate Medical Director and Clinical Trial Advisor & Medical Safety Monitor
Chairman and Consultant
Age: 40
Compensation as of Fiscal Year 2012.

Callisto Pharmaceuticals, Inc. Key Developments

Callisto Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Jan 14, 2013
Jan 3 13

Callisto Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Jan 14, 2013., at 13:00 US Eastern Standard Time. Location: Callisto's offices at 420 Lexington Avenue. Agenda: To consider the recent announcement by Synergy Pharmaceuticals Inc., of the results of its Phase IIb/III clinical trial.

Callisto Pharmaceuticals, Inc. announced delayed 10-Q filing
Nov 14 12

On 11/14/2012, Callisto Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Callisto Pharmaceuticals, Inc. announced delayed 10-Q filing
Aug 14 12

On 08/14/2012, Callisto Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
Saladax Biomedical, Inc. United States
Anterion Therapeutics, Inc. United States
Pathfinder Management, Inc. United States
Edwards Lifesciences Cardiovascular Resources Inc. United States
Eaton Scientific Systems Ltd. United States

Recent Private Companies Transactions

Type
Date		 Target
Merger/Acquisition
July 20, 2012 		--
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Callisto Pharmaceuticals, Inc., please visit www.callistopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close